Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00614029
Recruitment Status : Completed
First Posted : February 13, 2008
Last Update Posted : November 25, 2009
Sponsor:
Information provided by:
Zogenix, Inc.

Brief Summary:
A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered by the Intraject system.

Condition or disease Intervention/treatment Phase
Pharmacokinetics Bioequivalence Device: Sumatriptan (via Intraject System) Phase 1

Detailed Description:
A single center, randomized, single-dose, open-label, partial-block, four-period, four-way crossover study in 54 healthy adult subjects to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered by the Intraject system compared to IMITREX STATdose at three injection sites (abdomen, thigh, and arm.)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Randomized, Open-Label, Single-Dose, Four-way Crossover Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System Versus IMITREX STATdose at Three Injection Sites in Healthy Adults
Study Start Date : December 2006
Actual Primary Completion Date : December 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Sumatriptan

Arm Intervention/treatment
Experimental: A
IMITREX -abd. to Intraject-abd. to IMITREX -thigh to Intraject-thigh
Device: Sumatriptan (via Intraject System)
0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt

Experimental: B
Intraject-abd. to IMITREX -abd. to Intraject-thigh to IMITREX -thigh
Device: Sumatriptan (via Intraject System)
0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt

Experimental: C
Intraject-abd to IMITREX -abd to Intraject-arm. to IMITREX -arm.
Device: Sumatriptan (via Intraject System)
0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt

Experimental: D
IMITREX-abd to Intraject-abd to IMITREX-arm. to Intraject-arm.
Device: Sumatriptan (via Intraject System)
0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt

Experimental: E
IMITREX-arm to Intraject-arm to IMITREX-thigh to Intraject-thigh
Device: Sumatriptan (via Intraject System)
0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt

Experimental: F
Intraject-thigh to IMITREX-thigh to Intraject-arm to IMITREX-arm
Device: Sumatriptan (via Intraject System)
0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt




Primary Outcome Measures :
  1. The area under the plasma concentration-time curve, maximal plasma concentration, time to maximal concentration, terminal elimination half-life, and apparent terminal elimination rate constant of sumatriptan will be determined at each of 3 sites [ Time Frame: one week ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects
  • Negative serum pregnancy test
  • Female subjects of child-bearing potential must agree to use acceptable birth control 3 weeks prior to and 2 weeks after study dosing.
  • Body Mass Index (BMI) and sufficient subcutaneous thickness, in the opinion of the investigator, for an injection into the abdomen, arm and thigh
  • Non-tobacco user
  • Adequate venous access in the left or right arm to allow collection of a number of blood samples
  • Fluent in the English language
  • Provide written informed consent to participate in the study and be willing to comply with the study procedures

Exclusion Criteria:

  • History within the previous 2 years of drug or alcohol dependence
  • Evidence of clinically relevant oral, cardiovascular, hematologic, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric or skin disorder
  • History of epilepsy or other neurologic disease
  • History of coronary disease, peripheral vascular disease, cerebrovascular accident, transient ischemic attack, uncontrolled hypertension, or signs/symptoms of ischemic heart disease
  • History of allergy, anaphylaxis, or hypersensitivity to sumatriptan or similar drugs including sulphonamides
  • History of scleroderma or any skin condition that may adversely affect the injection or absorption of subcutaneously administered medications
  • Tattoos or birthmarks in the lateral thigh, abdominal area or arm (deltoid) that are large enough to restrict injection site selection and/or evaluation
  • Positive screening test for HIV antibodies, Hepatitis B surface antigen, or Hepatitis C antibody
  • Positive results on illicit drug test at Screening or at Check-in
  • Use of any prescription medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00614029


Locations
Layout table for location information
United States, Texas
Covance, Inc
Dallas, Texas, United States, 75247
Sponsors and Collaborators
Zogenix, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Patricia Chandler, MD Covance

Layout table for additonal information
Responsible Party: Stephen J. Farr, Ph.D/ President and COO, Zogenix, Inc
ClinicalTrials.gov Identifier: NCT00614029     History of Changes
Other Study ID Numbers: ZX001-0601
First Posted: February 13, 2008    Key Record Dates
Last Update Posted: November 25, 2009
Last Verified: November 2009
Keywords provided by Zogenix, Inc.:
sumatriptan
Injections
Subcutaneous
Additional relevant MeSH terms:
Layout table for MeSH terms
Sumatriptan
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs